drugset / Trial / NCT05322577
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
Non-randomizedSequentialOpen-labelBasic science
Summary
The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.
Timeline
- Start
- 2022-05-17
- Primary completion
- 2025-11-21
- Completion
- 2026-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemarituzumab | Monoclonal antibody | — | Intravenous |
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | S-1 | Small molecule | — | Oral |
| Background | Oxaliplatin | Small molecule | — | Intravenous |